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Clinical trials in inflammatory bowel disease (IBD) are evolving at a rapid pace by employing central reading for endoscopic
mucosal assessment in a field that was, historically, largely based on assessments by local physicians. This transition from local
to central reading carries with it numerous technical, operational, and scientific challenges, many of which can be resolved
by imaging core laboratories (ICLs), a concept that has a longer history in clinical trials in a number of diseases outside the
realm of gastroenterology. For IBD trials, ICLs have the dual goals of providing objective, consistent assessments of endo-
scopic findings using central-reading paradigms whilst providing important expertise with regard to operational issues and
regulatory expectations. This review focuses on current approaches to using ICLs for central endoscopic reading in IBD trials.
Keywords: inflammatory bowel disease; clinical trials; imaging core laboratories
INTRODUCTION
Physicians and pharmaceutical companies designing clinical
trials of experimental therapies for inflammatory bowel
disease (IBD) face several challenges. Contemporary IBD
trials rely on endoscopic endpoints for determining patient
eligibility and drug efficacy. Mucosal healing is used as one
of the most reliable objective markers for treatment effi-
cacy [1, 2]. Historically, assessment of mucosal healing has
been accomplished using static images of the small and
large bowel. In recent years, there has been a predominant
trend towards centralization of endoscopic evaluations re-
lating to studies evaluating both experimental drugs and
novel scoring systems in IBD. This centralization rests on
assessment of full-length videos of colonoscopies and
sigmoidoscopies, in order to most closely record the best
view, or reflect the view of the clinical site [1, 3]. The
incorporation of a video component into IBD disease eval-
uation creates new technical challenges for sponsors of clin-
ical trials and research studies, since video acquisition is not
yet the standard of care in clinical endoscopy suites.
Compared with still images, video is more challenging to
acquire and may require segmental annotation. Further,
the need to archive and transmit video data from clinical
sites to a central database in a standardized format creates
operational challenges for all parties involved in an IBD
clinical trial.
In contrast to trials in rheumatology, neuroscience and
cardiology—in which objective eligibility and efficacy end-
points are typically assessed centrally by a research team—
clinical trials in IBD often rely on the interpretation of
endoscopic findings by local participating physicians or
principal investigators (PIs), as well as on assessment by an
expert gastroenterologist functioning as a central reader.
 The Author(s) 2014. Published by Oxford University Press and the Digestive Science Publishing Co. Limited.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/
licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly
cited.This increases the chance of potential discord between of-
ficial local interpretations vs central interpretations. While
one may think that the duty endoscopist would be best
equipped to provide the most accurate score, there is in-
creasing evidence to suggest otherwise; this was high-
lighted in a recent review of a study on mesalamine in
ulcerative colitis (UC), in which there was no statistical dif-
ference between treatment and placebo [4]. As the authors
state, one possible explanation could be that 31% of the
subjects enrolled by PIs should actually not have been
included in the study. Although the PIs assessed these sub-
jects as exhibiting the minimum disease activity on endo-
scopy required for inclusion into the study, this set of
subjects were read for efficacy by the central read and
found that the subjects did not have the minimum
degree of disease activity on endoscopy for study eligibility.
A retrospective analysis indicates that had the trial been
conducted with central readers assessing subjects for elig-
ibility and excluded these subjects, the study would have
demonstrated statistically significant efficacy, with results
similar to those of other trials of mesalamine. [5].
In addition to technical and operational challenges, clin-
ical trials in IBD also lack standardized approaches to the
design of centralized reading facilities for assessment of
mucosal healing, compared with other fields such as oncol-
ogy or rheumatology, where read design is a widely dis-
cussed and well documented topic [6–12]. These areas of
clinical trials enjoy specific, documented, regulatory guid-
ance; for example, in rheumatology there are regulatory
documents guiding sponsors on the use of two indepen-
dent central readers, blinded to treatment arm and time
point, for assessment of structural progression of disease on
serial radiographs [13]. A recent meta-analysis shows that
this paradigm is widely instituted for all phases of clinical
trials in rheumatology [14]. On the other hand, study de-
signs in IBD trials vary significantly, with no consensus re-
garding optimal methodologies for read paradigm (image
review methodology), approaches to assessment of inter-
and intra-observer variability, or the appropriateness of ad-
judication that seeks to resolve differences in interpreta-
tion (Table 1).
In the pharmaceutical industry, ICLs have played a critical
role in the development and approval of a wide variety of
new therapies [15–21]. ICLs are likely play an increasingly
important role as IBD trial methodology matures and be-
comes more standardized. An important first step for ICLs is
to help improve the accuracy of IBD endpoints through the
use of experienced, centralized readers.
For IBD trials, ICLs are taking on the important role of
managing complex video data from sigmoidoscopies and
colonoscopies, acquired from large multi-centered studies,
in support of eligibility criteria as well as safety and efficacy
endpoints.
ENDOSCOPIC VIDEO ASSESSMENT
AND ICL WORKFLOW
Assessments in IBD trials are generally based on one of sev-
eral endoscopic scoring criteria, including the modified
Baron’s, Mayo, UCEIS, Simple Endoscopic Scoring in Crohn’s
(SES-CD), or Crohn’s Disease Endoscopic Index of Severity
(CDEIS) [3, 22–26]. As an example of the ICL workflow for
anIBDtrial,patientsenrolledwithactivediseaseundergoan
endoscopic assessment at entry and at a designated follow-
up after initiating therapy to assess drug efficacy. The gas-
troenterologist performing the initial endoscopy would
record a video of the examination, which is either mailed
as a hard copy to the central reading site, or directly up-
loaded to a central database via an FTP site. Video recording
in a standardized format can be difficult, depending on the
set-up of the endoscopy suite. Additionally, certain scoring
systems require anatomic annotations to be embedded in
the video, to ensure that central readers are scoring the
same anatomic segments. Purpose-built software packages
are being designed for endoscopic evaluation, which can
facilitate recording, whilst allowing for annotation record-
ing and simplified data uploads. Once a video has been ana-
lysed for resolution and quality by the ICL, it can be
uploaded to a central reader’s remote workstation for
review and scoring, based upon a set of pre-defined queries
and parameters in the study protocol. In this scenario, video
data often needs to be reviewed expeditiously (typically
within 24 hours of central upload), in order to confirm deci-
sions regarding trial eligibility.
The ICLs also have an important role in calibrating the
various steps in this process and making sure that all can
be completed to a minimum standard and ideally at the
highest quality; this includes verifying the local site’s ability
to record a high-quality video and submit or upload it to the
central database. It is critical that this step be accomplished
before the evaluation of a potential patient for inclusion
into a trial. Study sites also rely on feedback from ICLs re-
garding technical factors, bowel preparation and mucosal
visualization, in order to optimize video capture and data
analysis. This ongoing feedback can be instrumental in stan-
dardized assessment in a global, multi-center, clinical trial.
In addition, a similar calibration is needed for the central
readers. While expert readers are aware of the scoring sys-
tems in IBD, mock cases may be used prior to initiation of a
trial—andpotentiallyatspecifiedintervalsduringthetrial—
to help ensure standardization of reader scoring and to im-
prove inter-observer agreement. To date, experience has
demonstrated that continued communication and feedback
from the central readers, who are adept at evaluating en-
doscopic videos and findings, can better identify which sites
are providing high-quality videos and opportunities for and
which are revealing opportunities for improvement.
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Imaging core laboratories in inflammatory bowel diseaseSPECIFIC APPROACHES TO
SUPPORTING A TRIAL WITH A
LOCAL AND CENTRAL READING
Historically, an experienced physician at a primary trial
location will serve as Principal Investigator, providing over-
view of over eligibility assessment and safety monitoring.
With an increased need for central reading in clinical trials
by regulatory authorities, sponsors designing IBD trials face
the challenge of balancing the role of a local GI endoscopist
with the utilization of an experienced central reader. The
balancing of the two parties has resulted in a myriad par-
adigms (Table 1), with some sponsors excluding local read-
ing entirely.
For IBD trials, central readers can provide unbiased con-
firmation of endoscopic findings, as compared with a local
PI [6], particularly in studies covering multiple sites, with
limited numbers of patients enrolled at each site. The use
of central readers can also yield cost savings and may con-
tribute to more accurate assessments of therapeutic effi-
cacy by reducing the occurrence of inappropriately
enrolled subjects.
Despite the use of standardized scoring systems and ap-
propriate training, in multi-site IBD studies there is still a
risk that inter-observer variability will significantly affect
data interpretation and sample size requirements. Central
validation of endoscopic scores helps ensure that each pa-
tient enrolled and monitored is assessed using exactly the
same criteria, irrespective of local expertise. This activity
helps reduce discord between a central reader and a local
physician, and creates an opportunity to implement im-
provements at local sites for endoscopic scoring, enrolment
criteria and other key issues.
ADVANTAGES AND
DISADVANTAGES TO IBD TRIAL
PARADIGMS
Eligibility designs
The major factors influencing an eligibility design are sci-
entific caliber, operational intricacy, and turnaround time.
Sponsors and ICLs have chosen to design specific studies
with custom designs based on sponsors’ budgets, reducing
local read bias or maximizing the rate of enrolment. For
example, among the paradigms listed in Table 1,
Paradigm 1 carries the advantage of employing both local
and central reading for determination of eligibility, whilst
avoiding adjudication by using the central read in case of a
discord. This can avoid the disadvantage of a delay in de-
termination of final eligibility, should an adjudicator be in-
volved—which is an extra operational step in the reading
process.
With turnaround time being of the utmost importance
for eligibility, the advantages of Paradigms 4 and 6 carry
with them the efficient approach of not utilizing local read-
ing at all for determination of eligibility, and consigning
the assessment of patient inclusion, using the Mayo scoring
system, solely to the central reader. The disadvantage
of the two similar paradigms is that the sponsor is only
receiving one assessment of eligibility. However, if further
studies confirm the findings of the previously-mentioned
mesalamine study [6], in which there was over-enrolment
due to local reading for eligibility, a paradigm based en-
tirely on central reading for eligibility may in fact be
superior.
Paradigms 3, 5, and 7 carry the advantage of involving
the assessments of both the local and central readers, in
order to achieve a higher degree of consensus between
the two parties. However, involving both local and central
readers demands resolution of differences of interpreta-
tion, should they occur through an adjudication read by a
2
nd central reader. This 2
nd central reader would score the
subject in the same manner as the first central reader; with
no knowledge of the local or 1
st central reader’s score and
with no knowledge of the subject s clinical information.
The advantage of this paradigm is that it provides an
opportunity to resolve a disagreement between local and
central reader assessment while the disadvantage is that
the paradigm involves another step in the read process
and thus an additional time allowance for eligibility
determination.
Efficacy designs
Just as eligibility designs vary between single- and double
assessments, so can efficacy designs. The simplest design is
to read the time points using a single reader paradigm. The
advantage, of course, is a cost, given that the reading of
scores such as the Mayo, UCEIS, or CDEIS can be quite costly,
even with just a single reading. Further, the advantage of a
single read is that it avoids the need to resolve a difference
of scoring that would result in a Further, the advantage of
a single read is that it avoids potential differences of scor-
ing. While Paradigms 1 and 6 utilize this strategy, they carry
the disadvantage of not including a second read to confirm
or refute the very important endpoint determinations of
mucosal healing among IBD studies.
Paradigms 2, 3, 4, 5 and 7 all utilize a double read, with
the first four designs involving two central readers and
Paradigm 7 taking a similar approach as described in the
eligibility scenarios, in which scoring criteria are assessed by
a local and a central reader. The advantage again is the
added weight of two assessments for a particular time
point or points. This paradigm matches that of the numer-
ous trials in rheumatoid arthritis, in which a double
read with an adjudicator is the ‘gold standard’ approach
and recommended by the regulatory authorities. The
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Harris Ahmad et al.disadvantage, of course, is the added expense of compen-
sating two readers and the need to resolve any differences
in scoring, either with two central readers one local and
one central.
Efficacy adjudication designs
A degree of discord is inevitable in a double read for eligi-
bility or efficacy; before the trial begins, it is important to
have a predetermined action plan to deal with it. One such
approach, as utilized in Paradigms 4, 5 and 6, is to employ
no adjudication at all. The advantage is, of course, reduced
cost, whilst on the other hand the disadvantage is the need
to resolve these sometimes severe differences in a manner
acceptable for analysis. There are several such methods,
such as simply averaging the scores or setting a difference
in score a priori that results in removal of the subject
from analysis. The disadvantages of these approaches
are the uncertainty of whether the methodology is scien-
tifically sound with published trial data supporting the
rational.
A second approach to resolving discordant scoring is to
determine a percentage of cases to be adjudicated before
the start of the study. For example, Paradigms 2 and 3
employ an approach in which the top 10% of most discor-
dant reading scores discordant reads would be assessed by
a third central reader for final decision; in other words,
analysis would be performed by the ICL to determine
which subjects had the greatest degree of difference in
change in interpretation between two central readers. If
one hundred cases were included in the read, 10 cases rep-
resenting the highest degree of discord on the change in
severity of the subjects would be assessed by a third central
reader, who would adjudicate choose which of the two
central reader scores were most agreeable and this score
would be the final score for the subject.
The first advantage of this paradigm is that it addresses
the need to resolve scoring differences in a portion of sub-
jects in which the scoring assessments of change in differ-
ence was the greatest. The second advantage is that it
allows for a predictable method of determining the
number of cases that would eventually need to be bud-
geted for adjudication reads. The first disadvantage is
that the arbitrarily chosen percentage or number of cases
may be above or below that which is scientifically neces-
sary. The second disadvantage is that the adjudication cases
cannot be assessed until the end of the study, when the
first two central reads have been completed, since the per-
centage of subjects chosen is based on the total number of
cases completed.
The first advantage of this threshold based approach is
that it is specifies in advance a degree of variance, allowing
for appropriate adjudication of a subject as needed. The
second advantage is, of course, that adjudication can be
done in a real-time fashion, instead of at the end of the
trial. The disadvantage is that the budget is not capped at
an expected number of adjudicated time points since the-
oretically a range of 0 to 100% of all subjects could meet
the threshold and be allocated for this adjudication read.
This could increase the sponsor budget for central reads
beyond expectations while also adding a time delay for
final score determination on a higher than expected reads.
CONCLUSION
Clinical trials in IBD pose significant challenges for drug
sponsors due to the incorporation of complex video data,
the lack of standardized approaches to the design of cen-
tral reading, as well as the difficulty of balancing local and
central reads. As a result, trials in this therapeutic area use a
multitude of reader paradigms, ranging from endoscopic
scoring made exclusively by the local endoscopist, to scor-
ing exclusively by the central reader, with little regulatory
guidance regarding the optimal paradigm for IBD trials
[27, 28]. As a response to these challenges—and armed
with experience from similar therapeutic areas—ICLs are
likely to play an increasingly important role in applying
robust, evidence-based methodologies, while promoting
more standardized approaches to endoscopic assessment
by local and central readers.
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